In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Incyte Corp (INCY). The company’s shares closed yesterday at $81.06.
According to TipRanks.com, Frahm is a 2-star analyst with an average return of 0.0% and a 53.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Magenta Therapeutics Inc, Unum Therapeutics Inc, and Blueprint Medicines.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte Corp with a $90.11 average price target, which is an 11.2% upside from current levels. In a report issued on February 5, SunTrust Robinson also maintained a Buy rating on the stock with a $90 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.33 and a one-year low of $57. Currently, Incyte Corp has an average volume of 1.63M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.
